Phase 1/2 Study of UI-102 in Selected Advanced Cancers
ConditionAdvanced Cancer
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorUnited Immunity, co., Ltd.
About this trial
This phase 1/2 first-in-human study is designed to assess the safety and efficacy of UI-102, a TLR7/8 agonist encapsulated in a Cholesteryl Pullulan Nanoparticle.
Eligibility criteria
Qualifiers
Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1,
18 Years and Older (adult, older adult),
Histologically confirmed advanced cancer,
Archived or fresh tumor tissue sample that must be confirmed as adequate,
Disqualifiers
central nervous system metastasis,
Ongoing or uncontrolled ascites or pleural effusion,
Significant ongoing toxicity from prior anticancer treatment,
Out-of-range laboratory values,
Trial design
Treatments tested in this trial
- UI-102
Treatment groups
140 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov